Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need


Cardiff Oncology Webcast and Conference Call: New Data from KRAS-mutated mCRC Lead Clinical Program
 January 18, 2022
 5:00pm - 5:30pm EST

Cardiff Oncology management will host a webcast and conference call on January 18, 2022 at 5:00 pm ET to present new data from its Phase 1b/2 trial in KRAS-mutated mCRC.  To join the webcast please click on the link provided. To participate by phone, please use the following dial-in information: U.S. Dial-In: 1-877-407-9208; International Dial-In: 1-201-493-6784; Conference ID: 13725845.